ClinicalTrials.gg
Active, not recruitingNCT03706690PACIFIC-5Updated Aug 6, 2026Results posted

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

A Phase 3 interventional study of Durvalumab and Placebo in Carcinoma, Non-Small-Cell Lung, sponsored by AstraZeneca. Active, not recruiting at 87 sites in 10 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
407
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
17th of 94
407 · median 74
Started
2018
with 7 others
Phase 3
17 of 94
3 open now
Primary completion
2024-06
later than 9 of 36 live
Registered
33rd of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by enrollment, is one of 8 that started in 2018, is one of 17 in phase 3, reaches primary completion later than 9 of the 36 other live ones, and was the 33rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.

Read the detailed description

Approximately 400 patients will be randomized in a 2:1 to receive treatment with durvalumab or placebo therapy. The primary objective of this study is to assess the efficacy of durvalumab treatment compared with placebo in terms of PFS.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • NSCLC
  • Double-Blind
  • PD-L1
  • MEDI4736
  • Durvalumab
  • PFS
  • OS
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 years
  2. Documented NSCLC and present with locally advanced, unresectable (Stage III) disease;
  3. Receipt of concurrent or sequential chemoradiation therapy,
  4. No progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy
  5. World Health Organization (WHO) PS of 0 or 1;
  6. No prior exposure to any anti , anti-PD-1, anti-PD-L1, or anti PD L2 antibodies, excluding therapeutic anticancer vaccines
  7. Adequate organ and marrow function required
  8. of at least 12 weeks
  9. Tumor PD-L1 status, with the Ventana SP263 PD-L1 IHC assay determined by a reference laboratory, must be known prior to randomization.
  10. Tumour sample requirements are as follows: Provision of a tumour tissue sample (newly acquired sample \<=3 months old is preferred, but an archived sample \<=6 months old is acceptable) in a quantity sufficient to allow for analysis.

Exclusion criteria

Exclusion Criteria:

  1. History of allogeneic organ transplantation, or another primary , or active primary immunodeficiency.
  2. Active or prior documented or inflammatory disorders
  3. Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written
  4. Active infection including tuberculosis (HCV), or (positive human immunodeficiency virus [HIV] 1/2 antibodies).
  5. Mixed small cell and NSCLC histology, sarcomatoid variant
  6. Any unresolved toxicity National Cancer Institute (NCI) (CTCAE) Grade ≥2 from the prior chemoradiation therapy.
  7. Receipt of within 30 days prior to the first dose of IP.
  8. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    Durvalumab Therapy

    Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/deterioration or confirmed radiological progression)

    Drug: Durvalumab

  • Placebo comparator
    Placebo Therapy

    Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)

    Other: Placebo

Interventions

  • Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] until clinical progression/ deterioration or confirmed radiological progression.

    Also known as: MEDI4736

  • OtherPlacebo

    Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)

    The PFS per Response Evaluation Criteria in Solid Tumors 1.1. (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression (PD) or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of \>=5 millimeters (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

Secondary outcomes

  1. Overall Survival (OS)

    The OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. Median OS was calculated using the Kaplan-Meier technique.

    Time frame: Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

  2. Progression-Free Survival (PFS) (Intent-to-Treat [ITT] Set)

    The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of \>=5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

    Time frame: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

  3. Percentage of Participants Alive at 24 Months (OS24)

    OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. The OS24 was defined as the Kaplan-Meier estimate of OS at 24 months after randomization.

    Time frame: Month 24

  4. Objective Response Rate (ORR)

    The ORR per RECIST 1.1 using BICR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) based on all participants in the subset of the analysis population including only those participants with measurable disease at baseline per BICR. The CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters as long as criteria for PD are not met.

    Time frame: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

  5. Duration of Response (DoR)

    The DoR per RECIST 1.1 using BICR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of \>=5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. The DoR was calculated using the Kaplan-Meier technique.

    Time frame: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

  6. Percentage of Participants Alive and Progression-Free at 12 and 18 Months (PFS12 and PFS18)

    The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of \>=5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. The PFS12 and PFS18 were defined as the Kaplan-Meier estimate of PFS per RECIST 1.1 as assessed by the Investigator at 12 and 18 months, respectively and both were obtained using the algorithm for the RECIST 1.1 site Investigator tumor data.

    Time frame: Months 12 and 18

  7. Time From Randomization to Second Progression (PFS2)

    PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy, or death. The date of the second progression was recorded by the Investigator and defined according to local standard clinical practice and could have involved any of objective radiological imaging, symptomatic progression, or death. Median time to PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

  8. Time to Death or Distant Metastases (TTDM)

    TTDM as per RECIST 1.1 using BICR was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that was outside of the radiation field according to RECIST 1.1. Median TTDM was calculated using the Kaplan-Meier technique.

    Time frame: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)

  9. Serum Concentration of Durvalumab

    Blood samples were collected to determine the concentration of durvalumab.

    Time frame: End of infusion on Cycle 1 Day 1, pre-infusion on Cycles 2 and 4 Day 1 and Month 3 follow-up (each cycle=28 days)

  10. Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

    Blood samples were collected to determine the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence was defined as the number of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as either treatment-induced (post-baseline ADA positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to \>=4-fold during the study period). Treatment-induced ADA was defined as ADA positive only post-baseline and not detected at baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive assessments with at least 16 weeks between the first and last positive assessment, or ADA positive at the last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment without fulfilling the conditions for persistently positive.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2 and 4 (each cycle=28 days)

  11. Change From Baseline in Patient-Reported Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Week 132

    Patient reported outcomes for 5 disease related symptoms was assessed using EORTC QLQ-Core 30 (C30) items questionnaire (fatigue, appetite loss) and EORTC QLQ-Lung Cancer module 13 (LC13) (dyspnoea, cough and pain in chest).An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, functional scales, and global health status scale with higher scores on global health status/QoL and functioning scales representing better health status/function, but higher scores on symptom scales/items representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as change from baseline of \>=10. Change from baseline in C30: global health status/QoL, physical functioning, fatigue, appetite loss and LC13: dyspnoea, cough and pain in chest are presented.

    Time frame: Baseline (Day 1) and Week 132

  12. Number of Participants With Positive Programmed Death Ligand 1 (PD-L1) Status Based on Overall Survival, Progression-Free Survival and Objective Response Rate

    Blood samples will be collected for clinical biomarker testing and a tumor specimen will be collected as per tumor specimen collection requirements. The specimen will be evaluated by immunohistochemistry to determine the expression of tumor specific antigens and immune markers. The PD-L1 is a biomarker and data for number of participants with its positive status will be presented.

    Time frame: Up to 9 years

07

Results

Posted Feb 12, 2025

Participant flow

This Phase III double-blind, placebo-controlled study was conducted at 82 investigational sites across 10 countries in participants with locally advanced, unresectable, non-small cell lung cancer (Stage III), who had not progressed following definitive, platinum-based, chemoradiation therapy (CRT).

Participant flow — Overall Study
MilestoneDurvalumabPlacebo
Started272135
Participants who received treatment271134
Intent-to-treat (itt) set272135
Modified intent-to-treat (mitt) set252129
Completed00
Not completed272135
Withdrew: Withdrawal by subject88
Withdrew: Death14375
Withdrew: Ongoing at dco12152

Outcome measures

PrimaryProgression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)

The PFS per Response Evaluation Criteria in Solid Tumors 1.1. (RECIST 1.1) using blinded independent central review (BICR) assessments was defined as the time from the date of randomization until the date of objective disease progression (PD) or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of \>=5 millimeters (mm), taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Median · months
Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)
monthsDurvalumabPlacebo
Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)14.0 (10.9 to 18.0)6.5 (5.4 to 13.8)
Statistical analysis
  • Durvalumab vs Placebo · Log Rank · p = 0.038 · Hazard ratio (hr): 0.75 · 95% CI 0.578 to 0.986Analysis performed using stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy (cCRT vs sCRT).
SecondaryOverall Survival (OS)

The OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. Median OS was calculated using the Kaplan-Meier technique.

Time frame:
Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Median · months
Overall Survival (OS)
monthsDurvalumabPlacebo
mITT set38.3 (28.9 to 42.8)32.5 (20.6 to 40.4)
ITT set38.4 (29.0 to 42.9)32.5 (20.6 to 40.4)
Statistical analysis
  • Durvalumab vs Placebo · Log Rank · p = 0.346 · Hazard ratio (hr): 0.87 · 95% CI 0.656 to 1.166Analysis performed using stratified log-rank test, adjusting for level of PD-L1 expression and prior therapy (cCRT vs. sCRT).
  • Durvalumab vs Placebo · Log Rank · p = 0.346 · Hazard ratio (hr): 0.87 · 95% CI 0.663 to 1.162Analysis performed using stratified log-rank test, adjusting for level of PD-L1 expression and prior therapy (cCRT vs. sCRT).
SecondaryProgression-Free Survival (PFS) (Intent-to-Treat [ITT] Set)

The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of \>=5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. Median PFS was calculated using the Kaplan-Meier technique.

Time frame:
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Median · months
Progression-Free Survival (PFS) (Intent-to-Treat [ITT] Set)
monthsDurvalumabPlacebo
Progression-Free Survival (PFS) (Intent-to-Treat [ITT] Set)14.1 (10.9 to 18.2)7.4 (5.5 to 13.8)
Statistical analysis
  • Durvalumab vs Placebo · Log Rank · p = 0.026 · Hazard ratio (hr): 0.74 · 95% CI 0.575 to 0.966Analysis performed using stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy (cCRT vs sCRT).
SecondaryPercentage of Participants Alive at 24 Months (OS24)

OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy. The OS24 was defined as the Kaplan-Meier estimate of OS at 24 months after randomization.

Time frame:
Month 24
Reported as:
Number · percentage of participants
Percentage of Participants Alive at 24 Months (OS24)
percentage of participantsDurvalumabPlacebo
mITT set60.7 (54.2 to 66.5)54.4 (45.2 to 62.7)
ITT set60.8 (54.7 to 66.5)54.6 (45.6 to 62.8)
SecondaryObjective Response Rate (ORR)

The ORR per RECIST 1.1 using BICR was defined as the percentage of participants with at least 1 visit response of complete response (CR) or partial response (PR) based on all participants in the subset of the analysis population including only those participants with measurable disease at baseline per BICR. The CR was defined as disappearance of all TLs since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis to \<10 mm. The PR was defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters as long as criteria for PD are not met.

Time frame:
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsDurvalumabPlacebo
mITT set27.620.7
ITT set27.119.7
Statistical analysis
  • Durvalumab vs Placebo · Regression, Logistic · p = 0.128 · Odds ratio (or): 1.51 · 95% CI 0.891 to 2.607
  • Durvalumab vs Placebo · Regression, Logistic · p = 0.105 · Odds ratio (or): 1.54 · 95% CI 0.915 to 2.638
SecondaryDuration of Response (DoR)

The DoR per RECIST 1.1 using BICR was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of \>=5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. The DoR was calculated using the Kaplan-Meier technique.

Time frame:
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Median · months
Duration of Response (DoR)
monthsDurvalumabPlacebo
mITT setNA (16.6 to NA)37.6 (5.4 to NA)
ITT setNA (20.7 to NA)37.6 (5.4 to NA)
SecondaryPercentage of Participants Alive and Progression-Free at 12 and 18 Months (PFS12 and PFS18)

The PFS per RECIST 1.1 using BICR assessments was defined as the time from the date of randomization until the date of objective PD or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anti-cancer therapy prior to progression. The PD was defined as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of \>=5 mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters. The PFS12 and PFS18 were defined as the Kaplan-Meier estimate of PFS per RECIST 1.1 as assessed by the Investigator at 12 and 18 months, respectively and both were obtained using the algorithm for the RECIST 1.1 site Investigator tumor data.

Time frame:
Months 12 and 18
Reported as:
Number · percentage of participants
Percentage of Participants Alive and Progression-Free at 12 and 18 Months (PFS12 and PFS18)
percentage of participantsDurvalumabPlacebo
PFS12, mITT set53.6 (47.0 to 59.7)42.7 (33.8 to 51.4)
PFS18, mITT set43.4 (36.9 to 49.7)34.1 (25.6 to 42.8)
PFS12, ITT set54.2 (47.9 to 60.1)42.5 (33.8 to 51.0)
PFS18, ITT set44.2 (37.9 to 50.3)33.4 (25.1 to 41.9)
SecondaryTime From Randomization to Second Progression (PFS2)

PFS2 was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy, or death. The date of the second progression was recorded by the Investigator and defined according to local standard clinical practice and could have involved any of objective radiological imaging, symptomatic progression, or death. Median time to PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Median · months
Time From Randomization to Second Progression (PFS2)
monthsDurvalumabPlacebo
mITT set26.4 (22.1 to 36.0)19.5 (14.7 to 28.9)
ITT set26.2 (22.0 to 34.8)19.5 (14.3 to 28.9)
Statistical analysis
  • Durvalumab vs Placebo · Log Rank · p = 0.275 · Hazard ratio (hr): 0.86 · 95% CI 0.648 to 1.138The analysis was performed using the stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy (cCRT vs. sCRT).
  • Durvalumab vs Placebo · Log Rank · p = 0.241 · Hazard ratio (hr): 0.85 · 95% CI 0.648 to 1.122The analysis was performed using the stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy (cCRT vs. sCRT).
SecondaryTime to Death or Distant Metastases (TTDM)

TTDM as per RECIST 1.1 using BICR was defined as the time from the date of randomization until the first date of distant metastasis or death in the absence of distant metastasis. Distant metastasis was defined as any new lesion that was outside of the radiation field according to RECIST 1.1. Median TTDM was calculated using the Kaplan-Meier technique.

Time frame:
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Reported as:
Median · months
Time to Death or Distant Metastases (TTDM)
monthsDurvalumabPlacebo
mITT set42.6 (33.2 to NA)NA (20.3 to NA)
ITT set42.6 (33.2 to NA)NA (20.3 to NA)
Statistical analysis
  • Durvalumab vs Placebo · Log Rank · p = 0.769 · Hazard ratio (hr): 1.06 · 95% CI 0.726 to 1.578The analysis was performed using the stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy (cCRT vs. sCRT).
  • Durvalumab vs Placebo · Log Rank · p = 0.812 · Hazard ratio (hr): 1.05 · 95% CI 0.726 to 1.539The analysis was performed using the stratified log-rank test, adjusting for the level of PD-L1 expression and prior therapy (cCRT vs. sCRT).
SecondarySerum Concentration of Durvalumab

Blood samples were collected to determine the concentration of durvalumab.

Time frame:
End of infusion on Cycle 1 Day 1, pre-infusion on Cycles 2 and 4 Day 1 and Month 3 follow-up (each cycle=28 days)
Reported as:
Mean · nanogram/milliliter
Serum Concentration of Durvalumab
nanogram/milliliterDurvalumab
Cycle 1 Day 1511415.541 ± 222137.0134
Cycle 2 Day 193929.182 ± 86188.4708
Cycle 4 Day 1138752.016 ± 73792.7522
Month 3 follow-up40303.562 ± 47725.6327
SecondaryNumber of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab

Blood samples were collected to determine the presence of ADAs and ADA-neutralizing antibodies (nAb) for durvalumab using validated assays. ADA prevalence was defined as the number of participants with positive ADA result at any time, baseline or post-baseline. ADA incidence was defined as either treatment-induced (post-baseline ADA positive only) or treatment-boosted ADA (baseline positive ADA titer that was boosted to \>=4-fold during the study period). Treatment-induced ADA was defined as ADA positive only post-baseline and not detected at baseline. Persistently positive was defined as having at least 2 post-baseline ADA positive assessments with at least 16 weeks between the first and last positive assessment, or ADA positive at the last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment without fulfilling the conditions for persistently positive.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2 and 4 (each cycle=28 days)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
ParticipantsDurvalumab
ADA positive at any visit (ADA prevalence)9
Treatment-emergent ADA positive (ADA incidence)3
ADA positive at both baseline and post-baseline1
Treatment-induced ADA3
ADA positive at baseline only5
Treatment-boosted ADA0
Persistently positive0
Transiently positive4
nAb positive2
SecondaryChange From Baseline in Patient-Reported Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Week 132

Patient reported outcomes for 5 disease related symptoms was assessed using EORTC QLQ-Core 30 (C30) items questionnaire (fatigue, appetite loss) and EORTC QLQ-Lung Cancer module 13 (LC13) (dyspnoea, cough and pain in chest).An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, functional scales, and global health status scale with higher scores on global health status/QoL and functioning scales representing better health status/function, but higher scores on symptom scales/items representing greater symptom severity. An improvement in symptoms were indicated by a negative change in score from baseline. A positive change in score from baseline indicated a deterioration of symptoms. A minimum clinically meaningful change was defined as change from baseline of \>=10. Change from baseline in C30: global health status/QoL, physical functioning, fatigue, appetite loss and LC13: dyspnoea, cough and pain in chest are presented.

Time frame:
Baseline (Day 1) and Week 132
Reported as:
Mean · units on a scale
Change From Baseline in Patient-Reported Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at Week 132
units on a scaleDurvalumabPlacebo
mITT set: EORTC QLQ-C30: Global health status/QoL78.95 ± 13.91874.21 ± 17.261
mITT set: EORTC QLQ-C30: Physical functioning90.76 ± 10.21692.38 ± 11.012
mITT set: EORTC QLQ-C30: Fatigue symptom10.14 ± 13.81413.76 ± 18.225
mITT set: EORTC QLQ-C30: Appetite loss symptom5.85 ± 12.7913.17 ± 10.026
mITT set: EORTC QLQ-LC13: Dyspnoea symptom15.98 ± 14.99811.11 ± 12.172
mITT set: EORTC QLQ-LC13: Cough symptom16.37 ± 21.00922.22 ± 21.943
mITT set: EORTC QLQ-LC13: Pain in chest symptom9.94 ± 16.6256.35 ± 13.412
ITT set: EORTC QLQ-C30: Global health status/QoL78.70 ± 13.94374.24 ± 16.846
ITT set: EORTC QLQ-C30: Physical functioning90.79 ± 10.12092.73 ± 10.869
ITT set: EORTC QLQ-C30: Fatigue symptom10.93 ± 14.86613.13 ± 18.026
ITT set: EORTC QLQ-C30: Appetite loss symptom5.29 ± 12.2793.03 ± 9.808
ITT set: EORTC QLQ-LC13: Dyspnoea symptom15.17 ± 14.97410.61 ± 12.112
ITT set: EORTC QLQ-LC13: Cough symptom15.87 ± 21.46721.21 ± 21.932
ITT set: EORTC QLQ-LC13: Pain in chest symptom10.05 ± 17.5927.58 ± 14.298
SecondaryNumber of Participants With Positive Programmed Death Ligand 1 (PD-L1) Status Based on Overall Survival, Progression-Free Survival and Objective Response Rate

Blood samples will be collected for clinical biomarker testing and a tumor specimen will be collected as per tumor specimen collection requirements. The specimen will be evaluated by immunohistochemistry to determine the expression of tumor specific antigens and immune markers. The PD-L1 is a biomarker and data for number of participants with its positive status will be presented.

Time frame:
Up to 9 years

Results for this outcome have not been posted.

Adverse events

Collected over From time of signature of informed consent up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab143/272 (52.6%)104/271 (38.4%)223/271 (82.3%)
Placebo75/135 (55.6%)45/134 (33.6%)94/134 (70.1%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventDurvalumabPlacebo
Radiation pneumonitisInjury, poisoning and procedural complications14/27112/134
PneumoniaInfections and infestations21/2714/134
PneumonitisRespiratory, thoracic and mediastinal disorders15/2716/134
Pneumonia bacterialInfections and infestations6/2712/134
COVID-19Infections and infestations5/2712/134
Hepatic function abnormalHepatobiliary disorders3/2712/134
Atrial fibrillationCardiac disorders1/2712/134
HaemoptysisRespiratory, thoracic and mediastinal disorders2/2712/134
Cerebral infarctionNervous system disorders4/2711/134
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders4/2710/134
Most frequent other events
Showing 10 of 29
Most frequent other events
EventDurvalumabPlacebo
Radiation pneumonitisInjury, poisoning and procedural complications52/27127/134
HypothyroidismEndocrine disorders51/27110/134
AnaemiaBlood and lymphatic system disorders41/27120/134
PneumoniaInfections and infestations35/27111/134
HyperthyroidismEndocrine disorders33/2718/134
CoughRespiratory, thoracic and mediastinal disorders32/27115/134
Upper respiratory tract infectionInfections and infestations30/27115/134
COVID-19Infections and infestations30/27113/134
Alanine aminotransferase increasedInvestigations27/2716/134
Aspartate aminotransferase increasedInvestigations25/2715/134

Baseline characteristics

The ITT set included all randomized participants.

Age, Continuous
Age, Continuous(years)DurvalumabPlaceboTotal
Mean61.7 ± 8.3361.9 ± 7.9661.7 ± 8.20
Sex: Female, Male
Sex: Female, Male(Participants)DurvalumabPlaceboTotal
Female251843
Male247117364
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DurvalumabPlaceboTotal
Hispanic or Latino505
Not Hispanic or Latino267135402
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DurvalumabPlaceboTotal
American Indian or Alaska Native000
Asian19797294
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7538113
More than one race000
Unknown or Not Reported000
08

Study locations

87 sites
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changchun, 510000, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610042, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400037, China
  • Research Site
    Fuzhou, 350011, China
  • Research Site
    Guangzhou, 510280, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Qingdao, 266042, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Wenzhou, 325000, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Hong Kong, 00000, Hong Kong
  • Research Site
    Bangalore, 560068, India
  • Research Site
    Bengaluru, 560076, India
  • Research Site
    Karamsad, 388325, India
  • Research Site
    Kolkata, 700160, India
  • Research Site
    Nashik, 422005, India
  • Research Site
    Vadodara, 390007, India
  • Research Site
    Culiacán, 80230, Mexico
  • Research Site
    Mexico City, 0 3100, Mexico
  • Research Site
    Mexico City, 11810, Mexico
  • Research Site
    México, 1400, Mexico
  • Research Site
    Monterrey, 64000, Mexico
  • Research Site
    San Luis Potosí City, 78250, Mexico
  • Research Site
    Bacolod, 6100, Philippines
  • Research Site
    Baguio City, 2600, Philippines
  • Research Site
    Cagayan de Oro, 9000, Philippines
  • Research Site
    Cebu, 6000, Philippines
  • Research Site
    Davao City, 8000, Philippines
  • Research Site
    Quezon City, 1100, Philippines
  • Research Site
    Quezon City, 1104, Philippines
  • Research Site
    San Juan City, 1502, Philippines
  • Research Site
    Bialystok, 15-540, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Tomaszów Mazowiecki, 97-200, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Kazan, Tatarstan, 420029, Russia
  • Research Site
    Kirov, 610021, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 121467, Russia
  • Research Site
    Murmansk, 183047, Russia
  • Research Site
    Novosibirsk, 630055, Russia
  • Research Site
    Novosibirsk, 630099, Russia
  • Research Site
    Obninsk, 249036, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Samara, 443031, Russia
  • Research Site
    Saransk, 430005, Russia
  • Research Site
    Volgograd, 400138, Russia
  • Research Site
    Daegu, 41944, South Korea
  • Research Site
    Gwangju, 61469, South Korea
  • Research Site
    Seoul, 08308, South Korea
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Tainan, 70403, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taipei, 114, Taiwan
  • Research Site
    Taipei, 235, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Adana, 01060, Turkey (Türkiye)
  • Research Site
    Ankara, 06340, Turkey (Türkiye)
  • Research Site
    Edirne, 22030, Turkey (Türkiye)
  • Research Site
    Istanbul, 34030, Turkey (Türkiye)
  • Research Site
    Konya, 42080, Turkey (Türkiye)
  • Research Site
    Malatya, 44100, Turkey (Türkiye)
09

References and documents

Publications

  • Wu YL, Wu L, Bi N, Cil T, Ge H, Zhu Z, Wang CL, Zhang W, Lv D, Mingyan E, Sun J, Pan Y, Krzakowski M, Dikilitas M, Sendur MAN, Kim YC, Yang Y, Mao R, Zhang B, Wang L. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. J Hematol Oncol. 2025 Dec 7;18(1):111. doi: 10.1186/s13045-025-01768-1. PubMed 41354932 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2024, 66 months.

Results were first posted in Feb 2025, 7 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 66 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2018
First posted
Oct 16, 2018
StartActual
Nov 27, 2018
Primary completionActual
Jun 23, 2024
CompletionEst.
Feb 26, 2027
Results first posted
Feb 12, 2025
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03706690
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 16, 2018
Start date
Nov 27, 2018
Primary completion
Jun 23, 2024
Completion
Feb 26, 2027 (estimated)
Results posted
Feb 12, 2025
Last update
Aug 6, 2026

Study contacts

Yilong Wu, MD
principal investigator · Guangdong General Hospital, Guangdong Lung Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion